Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
García-Corbacho J, Indacochea A, González Navarro AE, Victoria I, Moreno D, Pesántez D, Angelats L, Modrego-Sanchez A, Sanfeliu E, Castillo O, Blasco P, Mezquita L, Viñolas N, Nogué M, Galván P, Adamo B, Basté N, Sauri T, Juan M, Prat A, Schettini F. García-Corbacho J, et al. Among authors: sauri t. Cancer Immunol Immunother. 2023 Jun;72(6):1725-1726. doi: 10.1007/s00262-023-03396-5. Cancer Immunol Immunother. 2023. PMID: 36809405 Free PMC article. No abstract available.
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
García-Corbacho J, Indacochea A, González Navarro AE, Victoria I, Moreno D, Pesántez D, Angelats L, Modrego-Sanchez A, Sanfeliu E, Castillo O, Blasco P, Mezquita L, Viñolas N, Nogué M, Galván P, Adamo B, Basté N, Sauri T, Juan M, Prat A, Schettini F. García-Corbacho J, et al. Among authors: sauri t. Cancer Immunol Immunother. 2023 Jun;72(6):1709-1723. doi: 10.1007/s00262-022-03360-9. Epub 2023 Jan 10. Cancer Immunol Immunother. 2023. PMID: 36625938 Free PMC article.
Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53-Mutated Metastatic Colorectal Cancer.
Lahoz S, Rodríguez A, Fernández L, Gorría T, Moreno R, Esposito F, Oliveres H, Albiol S, Saurí T, Pesantez D, Riu G, Cuatrecasas M, Jares P, Pedrosa L, Pineda E, Postigo A, Castells A, Prat A, Maurel J, Camps J. Lahoz S, et al. Among authors: sauri t. Cancers (Basel). 2022 Nov 30;14(23):5921. doi: 10.3390/cancers14235921. Cancers (Basel). 2022. PMID: 36497403 Free PMC article.
Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice.
Fernández-Montes A, de Velasco G, Aguín S, Farriols C, Guirado-Risueño M, Jerviz-Guía VG, Baeza-Nadal MV, Chicas-Sett R, Fírvida JL, García-Navalón F, Martín P, Perezagua-Marín C, Rodríguez D, Santamaría J, Saurí T, Cobo M. Fernández-Montes A, et al. Among authors: sauri t. Curr Treat Options Oncol. 2021 Feb 26;22(3):26. doi: 10.1007/s11864-021-00816-5. Curr Treat Options Oncol. 2021. PMID: 33635493 Review.
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
Jimenez-Fonseca P, Carmona-Bayonas A, Martínez de Castro E, Custodio A, Pericay Pijaume C, Hernandez R, Aguado G, Castro Unanua N, Cano JM, López F, Garrido M, Fernández Montes A, Visa L, Sánchez Cánovas M, Limón ML, Martínez Lago N, Pimentel P, Hurtado A, Azkárate A, Longo F, Diez M, Arias-Martinez A, Sauri T, Martín Carnicero A, Mangas M, Martín Richard M, Granja M, Ramchandani A, Hernández Pérez C, Cerdá P, Gil-Negrete A, Calvo M, Vidal Tocino R, Gallego J. Jimenez-Fonseca P, et al. Among authors: sauri t. Gastric Cancer. 2021 Mar;24(2):445-456. doi: 10.1007/s10120-020-01116-x. Epub 2020 Sep 24. Gastric Cancer. 2021. PMID: 32970266 Free PMC article.
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F, Jimenez-Fonseca P, Carmona-Bayonas A, Arrazubi V, Hernandez R, Cano JM, Custodio A, Pericay Pijaume C, Aguado G, Martínez Lago N, Sánchez Cánovas M, Cacho Lavin D, Visa L, Martinez-Torron A, Arias-Martinez A, López F, Limón ML, Vidal Tocino R, Fernández Montes A, Alsina M, Pimentel P, Reguera P, Martín Carnicero A, Ramchandani A, Granja M, Azkarate A, Martín Richard M, Serra O, Hernández Pérez C, Hurtado A, Gil-Negrete A, Sauri T, Morales Del Burgo P, Gallego J. Alvarez-Manceñido F, et al. Among authors: sauri t. Gastric Cancer. 2021 Jul;24(4):926-936. doi: 10.1007/s10120-021-01169-6. Epub 2021 Mar 2. Gastric Cancer. 2021. PMID: 33651195
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
Jimenez-Fonseca P, Carmona-Bayonas A, Martinez-Torron A, Alsina M, Custodio A, Serra O, Cacho Lavin D, Limón ML, Sauri T, López F, Visa L, Granja M, Martínez Lago N, Arrazubi V, Vidal Tocino R, Hernandez R, Aguado G, Cano JM, Martín Carnicero A, Mangas M, Pimentel P, Fernández Montes A, Macias Declara I, Longo F, Ramchandani A, Martín Richard M, Hurtado A, Azkarate A, Hernández Pérez C, Serrano R, Gallego J; AGAMENON-SEOM study group. Jimenez-Fonseca P, et al. Among authors: sauri t. Ther Adv Med Oncol. 2021 Jun 17;13:17588359211019672. doi: 10.1177/17588359211019672. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34211587 Free PMC article.
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors.
Auclin E, Vuagnat P, Smolenschi C, Taieb J, Adeva J, Nebot-Bral L, Garcia de Herreros M, Vidal Tocino R, Longo-Muñoz F, El Dakdouki Y, Martín-Romano P, Gaba L, Saurí T, Oliveres H, Castañón E, Garcia-Carbonero R, Besse B, Massard C, Mezquita L, Hollebecque A. Auclin E, et al. Among authors: sauri t. Cancers (Basel). 2021 Jul 27;13(15):3776. doi: 10.3390/cancers13153776. Cancers (Basel). 2021. PMID: 34359675 Free PMC article.
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.
Arias-Martinez A, Martínez de Castro E, Gallego J, Arrazubi V, Custodio A, Fernández Montes A, Diez M, Hernandez R, Limón ML, Cano JM, Vidal-Tocino R, Macias I, Visa L, Martin Richard M, Sauri T, Hierro C, Gil M, Cerda P, Martínez Moreno E, Martínez Lago N, Mérida-García AJ, Gómez González L, García Navalón FJ, Ruiz Martín M, Marín G, López-López F, Ruperez Blanco AB, Fernández AF, Jimenez-Fonseca P, Carmona-Bayonas A, Alvarez-Manceñido F. Arias-Martinez A, et al. Among authors: sauri t. Clin Transl Oncol. 2024 Feb 15. doi: 10.1007/s12094-024-03388-6. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38361134
29 results